Clinical research on pulmonary hypertension from a 2025 perspective: a narrative review
Qianwen Bai, Haoyu Liu, Hongquan Wang, Yao Yao, Jia Deng, Tao Wang · 2026
Read Clinical research on pulmonary hypertension from a 2025 perspective: a narrative review by Qianwen Bai, Haoyu Liu, Hongquan Wang, Yao Yao, Jia Deng, Tao Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13266839.txt.
Description
Qianwen Bai and colleagues review in 2026 a year of rapid change in pulmonary hypertension research, focusing on studies published during 2025. The condition raises pressure in lung arteries and strains the right side of the heart toward failure. Their narrative review searched for trials, registries, and studies on diagnosis, markers, and treatment with clear clinical value.
Diagnosis grew sharper through new biomarkers, imaging, and artificial intelligence tools for sorting patients by risk. Treatment shifted beyond widening blood vessels toward reversing harmful vessel remodeling, led by sotatercept and its widening validation. Older drug pathways were used more precisely, and attention grew for therapies aimed at the right ventricle itself. The authors see a stronger base for longer, better lives.
Catalog record
| CREATOR | Qianwen Bai, Haoyu Liu, Hongquan Wang, Yao Yao, Jia Deng, Tao Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |